Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Kantarjian HM"" wg kryterium: Autor


Tytuł :
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Autorzy :
Verstovsek S
Gotlib J
Gupta V
Atallah E
Mascarenhas J
Quintas-Cardama A
Sun W
Sarlis NJ
Sandor V
Levy RS
Kantarjian HM
Mesa RA
Pokaż więcej
Temat :
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
OncoTargets and Therapy, Vol 2014, Iss default, Pp 13-21 (2013)
Opis pliku :
electronic resource
Relacje :
http://www.dovepress.com/management-of-cytopenias-in-patients-with-myelofibrosis-treated-with-r-a15309; https://doaj.org/toc/1178-6930
Dostęp URL :
https://doaj.org/article/20ef8ffcd4bd483c8ee5ce6548eca53a
Czasopismo naukowe
Tytuł :
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
Autorzy :
Wang X
Roy A
Hochhaus A
Kantarjian HM
Chen TT
Shah NP
Pokaż więcej
Temat :
Therapeutics. Pharmacology
RM1-950
Źródło :
Clinical Pharmacology : Advances and Applications, Vol 2013, Iss Issue 1, Pp 85-97 (2013)
Opis pliku :
electronic resource
Relacje :
http://www.dovepress.com/differential-effects-of-dosing-regimen-on-the-safety-and-efficacy-of-d-a13299; https://doaj.org/toc/1179-1438
Dostęp URL :
https://doaj.org/article/dd2f90b8c8f34ef1bf5ded8418898035
Czasopismo naukowe
Tytuł :
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Autorzy :
Cortes, JE
Tallman, MS
Schiller, GJ
Trone, D
Gammon, G
Goldberg, SL
Perl, AE
Marie, J-P
Martinelli, G
Kantarjian, HM
Levis, MJ
Pokaż więcej
Temat :
Gastrointestinal Diseases
Leukemia
Acute
Kaplan-Meier Estimate
Protein Kinase Inhibitors
Young Adult
Drug
fms-Like Tyrosine Kinase 3
Myeloid
Gene Duplication
Salvage Therapy
Dose-Response Relationship
Female
Immunology
Antineoplastic Agents
Tandem Repeat Sequences
Benzothiazoles
Aged
Oncogene Proteins
Middle Aged
Hematologic Diseases
Fusion
Cardiorespiratory Medicine and Haematology
Heart Diseases
Clinical Sciences
Adult
Paediatrics and Reproductive Medicine
Humans
Phenylurea Compounds
Male
Źródło :
Cortes, JE; Tallman, MS; Schiller, GJ; Trone, D; Gammon, G; Goldberg, SL; et al.(2018). Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. BLOOD, 132(6), 598 - 607. doi: 10.1182/blood-2018-01-821629. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1zw0t5wd
Opis pliku :
application/pdf
Tytuł :
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
Autorzy :
Nicolini, FE
Basak, GW
Kim, DW
Olavarria, E
Pinilla-Ibarz, J
Apperley, JF
Hughes, T
Niederwieser, D
Mauro, MJ
Chuah, C
Hochhaus, A
Martinelli, G
DerSarkissian, M
Duh, MS
McGarry, LJ
Kantarjian, HM
Cortes, JE
Pokaż więcej
Temat :
Retrospective Studies
INHIBITORS
Oncology & Carcinogenesis
ACUTE LYMPHOBLASTIC-LEUKEMIA
Kaplan-Meier Estimate
Pyridazines
RESISTANT
Multivariate Analysis
Oncology
1112 Oncology And Carcinogenesis
Cancer Research
Original Article
hemic and lymphatic diseases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
Survival Rate
ponatinib
MARGINAL STRUCTURAL MODELS
CHRONIC MYELOID-LEUKEMIA
chronic myeloid leukemia (CML)
Female
PHASE-2
Antineoplastic Agents
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Life Sciences & Biomedicine
Stem Cell Transplantation
allogeneic stem cell transplantation (allo‐SCT)
Aged
Middle Aged
Disease Site
allogeneic stem cell transplantation (allo-SCT)
Treatment Outcome
Blast Crisis
Hematologic Malignancies
Mutation
Science & Technology
Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL)
Original Articles
Adult
Philadelphia Chromosome
Humans
Imidazoles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Proportional Hazards Models
threonine to isoleucine mutation at codon 315 (T315I)
Transplantation, Homologous
Źródło :
Cancer. 123
Opis pliku :
ELETTRONICO
Tytuł :
LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL
Autorzy :
Cortes, JE
Pinilla-Ibarz, J
Le Coutre, PD
Paquette, R
Chuah, C
Nicolini, FE
Apperley, JF
Khoury, HJ
Talpaz, M
Baccarani, M
Lustgarten, S
Haluska, FG
Guilhot, F
Deininger, MW
Hochhaus, A
Hughes, TP
Shah, NP
Kantarjian, HM
Pokaż więcej
Temat :
Science & Technology
Life Sciences & Biomedicine
Hematology
Immunology
1102 Cardiovascular Medicine And Haematology
Źródło :
21st Congress of the European Hematology Association
Tytuł :
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
Autorzy :
Krug, U
Ravandi, F
Ritchie, EK
Sayar, H
Lancet, JE
Craig, MD
Vey, N
Strickland, SA
Schiller, GJ
Jabbour, E
Erba, HP
Pigneux, A
Horst, H-A
Recher, C
Klimek, VM
Cortes, J
Roboz, GJ
Craig, AR
Fox, JA
Ward, R
Smith, JA
Acton, G
Mehta, C
Kantarjian, HM
Stuart, RK
Pokaż więcej
Źródło :
Krug, U; Ravandi, F; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; et al.(2015). Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study. Oncology Research and Treatment, 38, 121 - 121. UCLA: Retrieved from: http://www.escholarship.org/uc/item/52n202nm
Opis pliku :
application/pdf
Tytuł :
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Autorzy :
Giles FJ
Coutre PL
Pinilla-Ibarz J
Larson RA
Gattermann N
Ottmann OG
Hochhaus A
Radich JP
Saglio G
Hughes TP
Martinelli G
Kim DW
Novick S
Gillis K
Fan X
Cortes J
Baccarani M
Kantarjian HM.
Pokaż więcej
Temat :
hemic and lymphatic diseases
CHRONIC MYELOID LEUKEMIA (CML)
neoplasms
Opis pliku :
STAMPA
Tytuł :
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Autorzy :
Kantarjian HM
Giles FJ
Bhalla KN
Pinilla-Ibarz JA
Larson RA
Gattermann N
Ottmann OG
Hochhaus A
Radich JP
Saglio G
Hughes TP
Martinelli G
Kim DW
Shou Y
Gallagher NJ
Blakesley R
Baccarani M
Cortes J
le Coutre PD.
Pokaż więcej
Temat :
CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
hemic and lymphatic diseases
NILOTINIB
Clinical Trials and Observations
Opis pliku :
STAMPA
Tytuł :
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
Autorzy :
Cortes JE
Baccarani M
Guilhot F
Druker BJ
Branford S
Kim DW
Pane F
Pasquini R
Goldberg SL
Kalaycio M
Moiraghi B
Rowe JM
Tothova E
De Souza C
Rudoltz M
Yu R
Krahnke T
Kantarjian HM
Pokaż więcej
Opis pliku :
STAMPA
Tytuł :
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Autorzy :
Branford S
Kim DW
Soverini S
Haque A
Shou Y
Woodman RC
Kantarjian HM
Martinelli G
Radich JP
Saglio G
Hochhaus A
Hughes TP
Müller MC
Branford, Susan
Kim, Dong-Wook
Soverini, Simona
Haque, Ariful
Shou, Yaping
Woodman, Richard C
Kantarjian, Hagop M
Pokaż więcej
Źródło :
Journal of Clinical Oncology; 12/10/2012, Vol. 30 Issue 35, p4323-4329, 7p
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies